Mursla Bio Partners with Global Pharma to Develop AI-Driven Biomarkers for MASH Precision Medicine
核心洞察
Mursla Bio (搜索) has announced a collaboration with a leading global pharmaceutical company to advance biomarker-guided precision medicine in metabolic dysfunction-associated steatohepatitis (搜索) (MASH (搜索)).
The partnership will utilize Mursla Bio (搜索)'s AI Precision Medicine Platform to generate hepatocyte (搜索)-specific extracellular vesicle profiles from blood samples to identify patients most likely to benefit from investigational MASH (搜索) therapies.
The collaboration leverages the same infrastructure that enabled Mursla Bio (搜索)'s EvoLiver (搜索) product to achieve FDA Breakthrough Device Designation, expanding the company's reach in hepatology beyond liver cancer (搜索) surveillance.
Mursla Bio (搜索), a leader in extracellular vesicle science focused on precision diagnostics for chronic diseases, has announced a strategic collaboration with a leading global pharmaceutical company to advance biomarker-guided drug development in metabolic dysfunction-associated steatohepatitis (搜索) (MASH (搜索)). The partnership aims to identify patients most likely to benefit from investigational MASH therapies through AI-driven biomarker analysis.
AI Platform Targets Liver-Specific Biomarkers
Under the collaboration, Mursla Bio (搜索)'s AI Precision Medicine Platform will generate hepatocyte (搜索)-specific extracellular vesicle (h-EV) profiles from blood samples collected from a well-characterized cohort of patients with MASH (搜索) and matched healthy controls. The partnership will explore mode-of-action related biomarkers and evaluate biomarker panels to stratify patients for the pharmaceutical company's investigational therapy.
The initial phase will focus on generating insights into liver tissue biology in MASH (搜索) by building tissue-labeled, high dimensional mRNA and protein datasets from h-EVs in blood. This data will help define mode-of-action related pathways and patient stratification signatures, while strengthening Mursla Bio (搜索)'s AI liver disease models developed through its MEV01 clinical study.
Expanding Beyond Cancer Surveillance
The collaboration complements Mursla Bio (搜索)'s lead product, EvoLiver (搜索)™, which was developed for liver cancer (搜索) surveillance among cirrhotic patients and achieved FDA Breakthrough Device Designation. The partnership broadens the clinical and translational reach of the company's clinically validated platform across metabolic liver diseases, using the same infrastructure to accelerate the translation of exploratory biomarkers into regulatory-grade companion diagnostics.
"This collaboration reflects the growing demand from global pharmaceutical leaders for our AI Precision Medicine Platform," said Pierre Arsène, Founder and CEO of Mursla Bio (搜索). "As the GLP-1 revolution reshapes obesity (搜索) management, MASH (搜索) is rapidly emerging as the next major therapeutic focus, and the need for precise liver-specific biomarkers has never been greater."
Addressing Growing MASH Burden
MASH (搜索) represents an advanced stage of fatty liver disease (搜索) that is strongly associated with the global rise in obesity (搜索) and type 2 diabetes (搜索). The condition affects 5-7% of the world's adult population, with more than 75% of those affected classified as overweight, obese, and living with type 2 diabetes. MASH is characterized by the buildup of excess fat in the liver, which causes inflammation and cell damage, and can progress to irreversible scarring (cirrhosis (搜索)) and, in some cases, lead to liver failure (搜索) or liver cancer (搜索).
"By profiling intact hepatocyte (搜索) biology protected within the cargo of h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care," Arsène added. "This partnership deepens our reach in hepatology, expanding on the foundation established with EvoLiver (搜索)."